Valuation: Fulgent Genetics, Inc.

Market Cap 567M 508M 467M 424M 792M 53.87B 806M 5.57B 2.24B 28.34B 2.13B 2.08B 89.37B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 567M 508M 467M 424M 792M 53.87B 806M 5.57B 2.24B 28.34B 2.13B 2.08B 89.37B EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.48x
Free-Float
48.89%
Yield 2026 *
-
Yield 2027 * -
1 day-4.89%
1 week+2.59%
1 month-3.19%
3 months+24.59%
6 months+45.93%
Current year-21.51%
1 week 20.08
Extreme 20.08
21.77
1 month 19.3
Extreme 19.3
22.78
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
31.04
5 years 13.46
Extreme 13.46
109.55
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 03/05/2022
Chief Executive Officer 70 13/05/2016
Director of Finance/CFO 58 01/01/2016
Director TitleAgeSince
Chairman 70 01/09/2016
Director/Board Member 76 01/08/2019
Director/Board Member 57 01/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Founder

-2,127 0.0069%
9/2/26 A Sell

Chief Technology Officer

-1,673 0.0055%
9/1/26 A Tax

Chief Financial Officer

-2,087 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
-4.89%+2.59%-8.15%-13.18% 567M
-0.09%-3.44%+15.48%+31.31% 115B
-1.02%+0.89%+2.94%+109.97% 98.85B
-4.98%+2.56%+108.26%+943.84% 59.72B
+1.44%+1.95%-6.04%+93.89% 30.06B
-1.84%+9.86%+42.30%+77.20% 29.34B
-0.43%+4.11%+43.12%+90.01% 27.71B
+0.99%+1.79%+32.33%+414.69% 21.75B
-1.58%+3.86%-19.91%-13.49% 20.66B
-.--%-0.63%-4.85%+31.05% 17.09B
Average -1.24%+2.52%+20.55%+176.53% 42.12B
Weighted average by Cap. -1.06%+1.07%+26.12%+208.22%

Financials

2026 *2027 *
Net sales 332M 297M 273M 248M 463M 31.5B 471M 3.26B 1.31B 16.57B 1.24B 1.22B 52.25B 383M 343M 315M 286M 534M 36.34B 544M 3.76B 1.51B 19.11B 1.44B 1.41B 60.28B
Net income -112M -100M -92.27M -83.6M -156M -10.63B -159M -1.1B -442M -5.59B -420M -411M -17.64B -79M -70.75M -65.08M -58.97M -110M -7.5B -112M -776M -312M -3.95B -296M -290M -12.44B
Net Debt - -
Projected Income Statement - Annual - Fulgent Genetics, Inc.
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
30/10/26 $20.62 -4.89% 201,370
29/10/26 $21.68 +0.74% 210,287
28/10/26 $21.52 +3.96% 397,563
27/10/26 $20.70 +2.37% 355,832
26/10/26 $20.22 +0.60% 191,243
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Fulgent Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20.62USD
Average target price
19.00USD
Spread / Average Target
-7.86%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fulgent Genetics, Inc.
  1. Stock Market
  2. Stocks
  3. FLGT Stock